Blastic Plasmacytoid Dendritic Cell Neoplasm Clinical Trials

31 clinical trials for Blastic Plasmacytoid Dendritic Cell Neoplasm across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant — RECRUITING · PHASE2
• Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases — RECRUITING · PHASE2
• Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients — RECRUITING · PHASE2
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — RECRUITING · PHASE1
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry — RECRUITING
• Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm — RECRUITING · PHASE2
• CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial — RECRUITING · PHASE1
• Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm — COMPLETED · PHASE1
• A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD — COMPLETED · PHASE2
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation — TERMINATED · PHASE2
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE2
• Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — COMPLETED · PHASE1
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm — ACTIVE_NOT_RECRUITING · PHASE1
• Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN — ACTIVE_NOT_RECRUITING · PHASE1
• Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia — COMPLETED · PHASE1
• Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant — TERMINATED · PHASE2
• Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. — TERMINATED
• Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. — TERMINATED · PHASE1
• Combination Chemotherapy in Patients With Newly Diagnosed BPDCN — OTHER · PHASE2
• PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies — COMPLETED · PHASE1
• Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. — COMPLETED
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma — TERMINATED · PHASE2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies — COMPLETED · NA
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN — TERMINATED · PHASE1
• DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes — COMPLETED · PHASE1
• Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) — COMPLETED
• SL-401 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM — NOT_YET_RECRUITING
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia — COMPLETED · PHASE1

Refine this search